The average twelve-month stock price prediction compiled from Wall Street analysts covering Protara Therapeutics (TARA) sits at approximately $26.25 per share. Financial institutions tracking the clinical-stage biopharmaceutical firm maintain overwhelmingly positive ratings, citing the potential commercial value of its targeted orphan drug indications and clinical pipeline advancements as primary catalysts driving projected equity appreciation over the coming year.